SOPHARMA AD (the “Company”) hereby informs that from 28 March 2013 up to and including 3 April 2013 the Company bought 1000 own shares representing 0.00076% of the share capital of the Company, to the total value of BGN 2370 on the Bulgarian Stock Exchange. The average price per share was BGN 2.37.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 3667347, representing 2.778% of the share capital of the Company.

Sopharma AD (the “Company”) notifies that for March 2013 Sopharma AD realized a decrease of sales revenues of 10% compared to the same period of 2012, including 12% increase of domestic sales and 20% decrease of export sales.

During the past three months Sopharma AD recorded a decrease of sales revenues of 4%, including 5% increase of domestic sales and 8% decrease of export sales compared to 2012.

SOPHARMA AD (the “Company”) hereby informs that from 4 April 2013 up to and including 10 April 2013 the Company bought 39486 own shares representing 0.03% of the share capital of the Company, to the total value of BGN 97648.86 on the Bulgarian Stock Exchange. The average price per share was BGN 2.47.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 3706833, representing 2.808% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 11 April 2013 up to and including 17 April 2013 the Company bought 158132 own shares representing 0.12% of the share capital of the Company, to the total value of BGN 405022.17 on the Bulgarian Stock Exchange. The average price per share was BGN 2.56.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 3864965, representing 2.93% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 18 April 2013 up to and including 24 April 2013 the Company bought 140703 own shares representing 0.107% of the share capital of the Company, to the total value of BGN 355773.63 on the Bulgarian Stock Exchange. The average price per share was BGN 2.53.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 4005668, representing 3.03% of the share capital of the Company.

Sopharma AD (the “Company”) notifies that in connection with the Easter Holiday the results for April 2013 will be published on 10 May 2013.

Sopharma AD (the “Company”) announces that the Company sold 20 000 ordinary registered shares with voting rights, representing 0.107% of the share of the capital of United Holding Doverie AD. After this transaction the share of Sopharma AD in the capital of United Holding Doverie AD decreased below 15% to 14.93%.

Sopharma AD (the “Company”) notifies that for April 2013 Sopharma AD realized same level of sales revenues compared to the same period of 2012, including 3% increase of domestic sales and 1% decrease of export sales.

During the past four months Sopharma AD recorded a decrease of sales revenues of 3%, including 4% increase of domestic sales and 6% decrease of export sales compared to 2012.

SOPHARMA AD (the “Company”) hereby informs that from 25 April 2013 up to and including 8 May 2013 the Company bought 108089 own shares representing 0.082% of the share capital of the Company, to the total value of BGN 281132.57 on the Bulgarian Stock Exchange.

The average price per share was BGN 2.60.The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 4113757, representing 3.12% of the share capital of the Company.

Pursuant to art.100k, par.1 of POSA we hereby notify, that the Board of Directors of Sopharma AD authorized the Executive Director to begin negotiations for the sale of all shares representing 85% of the capital of the subsidiary Extab Corporation, owned by Sopharma AD. The negotiations will be conducted as part of the strategy for development of the original products of Sopharma AD on new markets, on which the Company does not possess the necessary resources for such actions in the near future.